| 1 |
33423619 | Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). | 2022 Apr |
2 |
| 2 |
34688013 | Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists. | 2022 Jan 5 |
4 |
| 3 |
34773566 | Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. | 2022 Mar |
1 |
| 4 |
34863048 | Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase. | 2022 May |
3 |
| 5 |
35051860 | CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. | 2022 Mar |
1 |
| 6 |
35200545 | Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress. | 2022 Jan 26 |
2 |
| 7 |
35306539 | A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. | 2022 Mar 19 |
2 |
| 8 |
35473510 | Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients. | 2022 Apr 26 |
1 |
| 9 |
32686977 | An in vitro approach to simulate the process of 5-fluorouracil degradation with dihydropyrimidine dehydrogenase: the process in accordance to the first-order kinetic reaction. | 2021 Jan |
6 |
| 10 |
32929530 | To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible? | 2021 Jan |
2 |
| 11 |
33491253 | Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. | 2021 Aug |
7 |
| 12 |
33544210 | Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. | 2021 May |
2 |
| 13 |
33648930 | Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer. | 2021 Apr 1 |
1 |
| 14 |
33755421 | The Interaction of Porcine Dihydropyrimidine Dehydrogenase with the Chemotherapy Sensitizer: 5-Ethynyluracil. | 2021 Apr 13 |
3 |
| 15 |
33895696 | Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. | 2021 Jun |
1 |
| 16 |
33965356 | Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. | 2021 Sep |
1 |
| 17 |
34069161 | Force Field Parameters for Fe2+4S2-4 Clusters of Dihydropyrimidine Dehydrogenase, the 5-Fluorouracil Cancer Drug Deactivation Protein: A Step towards In Silico Pharmacogenomics Studies. | 2021 May 14 |
1 |
| 18 |
34276810 | Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes. | 2021 |
2 |
| 19 |
34411894 | Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. | 2021 Dec 5 |
5 |
| 20 |
34449540 | Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature. | 2021 Jul 27 |
5 |
| 21 |
34498246 | [New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings]. | 2021 Aug 10 |
1 |
| 22 |
34506675 | Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. | 2021 Dec |
1 |
| 23 |
34571731 | Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. | 2021 Aug 31 |
1 |
| 24 |
34645611 | Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. | 2021 Dec 1 |
2 |
| 25 |
34717904 | Mammalian dihydropyrimidine dehydrogenase. | 2021 Dec 15 |
1 |
| 26 |
34901834 | A narrative review of genetic factors affecting fluoropyrimidine toxicity. | 2021 Dec |
2 |
| 27 |
31778273 | Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. | 2020 Feb |
4 |
| 28 |
31871216 | Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. | 2020 Feb |
8 |
| 29 |
32088343 | S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer. | 2020 May |
1 |
| 30 |
32377978 | Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. | 2020 Dec |
1 |
| 31 |
32382808 | Phase I pharmacological study of continuous chronomodulated capecitabine treatment. | 2020 May 7 |
2 |
| 32 |
32474853 | Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update. | 2020 Dec |
1 |
| 33 |
32546132 | Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. | 2020 Jun 16 |
2 |
| 34 |
32546724 | SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression. | 2020 Jul |
4 |
| 35 |
32946963 | Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft. | 2020 Dec 28 |
4 |
| 36 |
32966231 | Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin. | 2020 Sep 23 |
4 |
| 37 |
33035787 | Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. | 2020 Dec |
1 |
| 38 |
33197222 | All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. | 2020 Dec |
1 |
| 39 |
33232506 | Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. | 2020 Nov 16 |
5 |
| 40 |
33238487 | Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. | 2020 Nov 23 |
2 |
| 41 |
33299409 | Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis. | 2020 |
1 |
| 42 |
33704179 | Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil. | 2020 Dec 18 |
6 |
| 43 |
28942723 | Case report of capecitabine toxicity and use of uridine triacetate. | 2019 Mar |
1 |
| 44 |
30226808 | Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer. | 2019 Feb |
8 |
| 45 |
30651398 | S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. | 2019 May |
7 |
| 46 |
30803213 | Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma | 2019 Feb 26 |
1 |
| 47 |
30831507 | Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report. | 2019 |
4 |
| 48 |
30858516 | The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. | 2019 Apr |
1 |
| 49 |
30894562 | Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research. | 2019 Mar 20 |
3 |
| 50 |
30898145 | Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report. | 2019 Mar 22 |
1 |